Literature DB >> 2504934

Race and diagnostic related group prospective hospital payment for medical patients.

E Muñoz, E Barrios, H Johnson, J Goldstein, K Mulloy, D Chalfin, L Wise.   

Abstract

The diagnostic related group (DRG) prospective hospital payment system has been on line for five years with no major changes implemented by the federal government. Data suggest that the DRG system may be inequitable to patients of lower socioeconomic status. We studied the consumption of hospital resources by race (ie, white vs black) for hospitalized medical patients using the DRG prospective payment system. All adult medical admissions (N = 30,097) were analyzed for a three-year period at a large academic medical center using the DRG "all payor" classification scheme in effect for New York State. We found that black patients (N = 3,373) had a significantly greater (P less than .0001) mean length of hospital stay and cost per patient (adjusted for DRG weight index) compared with white patients (N = 26,724). Black patients also exposed the medical center to greater (P less than .0001) financial risk compared with white patients, as measured by outliers and losses under DRGs. Black patients (P less than .0001) had a significantly higher proportion of emergency admissions to the hospital, a greater severity of illness (as measured by total International Classification of Diseases-9-Clinical Modification codes) (P less than .0001), and higher diagnostic costs (P less than .0001) for each episode of illness. These data suggest that at our medical center black medical patients may consume more hospital resources (adjusted for DRG case mix) compared with whites. It is important that methods to modify DRG prospective hospital payment for medical diseases be considered to provide more equitable DRG reimbursement for black Americans in the future.

Entities:  

Mesh:

Year:  1989        PMID: 2504934      PMCID: PMC2626048     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  6 in total

1.  The financial effects of emergency department-generated admissions under prospective payment systems.

Authors:  E Muñoz; A Laughlin; D M Regan; I Teicher; I B Margolis; L Wise
Journal:  JAMA       Date:  1985-10-04       Impact factor: 56.272

2.  Surgonomics: the identifier concept. Hospital charges in general surgery and surgical specialties under prospective payment systems.

Authors:  E Muñoz; D M Regan; I B Margolis; L Wise
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

3.  Medicare begins prospective payment of hospitals.

Authors:  J K Iglehart
Journal:  N Engl J Med       Date:  1983-06-09       Impact factor: 91.245

4.  Measuring severity of illness: comparisons across institutions.

Authors:  S D Horn
Journal:  Am J Public Health       Date:  1983-01       Impact factor: 9.308

5.  Financial risk, hospital cost, complications, and comorbidities in surgical noncomplication- and noncomorbidity-stratified diagnostic related groups.

Authors:  E Munoz; H Sterman; J Cohen; J Goldstein; I B Margolis; L Wise
Journal:  Ann Surg       Date:  1988-03       Impact factor: 12.969

6.  Diagnosis related groups and the transfer of general surgical patients between hospitals.

Authors:  E Muñoz; R Soldano; H Gross; D Chalfin; K Mulloy; L Wise
Journal:  Arch Surg       Date:  1988-01
  6 in total
  3 in total

Review 1.  Changes in medicare reimbursement: impact on therapy for benign prostatic hyperplasia.

Authors:  Robert F Donnell
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 3.092

2.  Implications of epidemiological studies for the disadvantaged elderly.

Authors:  F M Sinex
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

3.  Assessing the performance of a method for case-mix adjustment in the Korean Diagnosis-Related Groups (KDRG) system and its policy implications.

Authors:  Sujeong Kim; Byoongyong Choi; Kyunghee Lee; Sangmin Lee; Sukil Kim
Journal:  Health Res Policy Syst       Date:  2021-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.